A61K 2039/555
Medicinal preparations containing antigens or antibodies: characterised by a specific combination antigen/adjuvant
Official title: {characterised by a specific combination antigen/adjuvant}
A61K2039/555 (Medicinal preparations containing antigens or antibodies: characterised by a specific combination antigen/adjuvant) appears on 7,629 US grants and 13,365 published applications in this corpus.
Search patents in A61K- Granted patents
- 7,629
- Published applications
- 13,365
- Assignees
- 3,875
- Inventors
- 19,596
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 8 | 0 |
| 1978 | 11 | 0 |
| 1979 | 12 | 0 |
| 1980 | 14 | 0 |
| 1981 | 12 | 0 |
| 1982 | 16 | 0 |
| 1983 | 11 | 0 |
| 1984 | 15 | 0 |
| 1985 | 19 | 0 |
| 1986 | 16 | 0 |
| 1987 | 23 | 0 |
| 1988 | 20 | 0 |
| 1989 | 19 | 0 |
| 1990 | 15 | 0 |
| 1991 | 20 | 0 |
| 1992 | 29 | 0 |
| 1993 | 25 | 0 |
| 1994 | 12 | 0 |
| 1995 | 23 | 0 |
| 1996 | 31 | 0 |
| 1997 | 45 | 0 |
| 1998 | 87 | 0 |
| 1999 | 96 | 0 |
| 2000 | 104 | 0 |
| 2001 | 105 | 44 |
| 2002 | 118 | 224 |
| 2003 | 94 | 341 |
| 2004 | 103 | 413 |
| 2005 | 93 | 386 |
| 2006 | 131 | 358 |
| 2007 | 118 | 344 |
| 2008 | 134 | 387 |
| 2009 | 165 | 437 |
| 2010 | 211 | 485 |
| 2011 | 194 | 525 |
| 2012 | 222 | 501 |
| 2013 | 222 | 443 |
| 2014 | 325 | 493 |
| 2015 | 339 | 569 |
| 2016 | 384 | 603 |
| 2017 | 435 | 611 |
| 2018 | 447 | 565 |
| 2019 | 445 | 631 |
| 2020 | 449 | 671 |
| 2021 | 447 | 684 |
| 2022 | 388 | 763 |
| 2023 | 380 | 825 |
| 2024 | 369 | 828 |
| 2025 | 383 | 716 |
| 2026 | 241 | 518 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Lipidated FLIPr and uses thereof in vaccine6 Oct 2026US 12,752,003 B2National Health Research Institutes
- Modular multiplatform system for mrna drug production8 Oct 2026US 2026/0306407 A1BioNTech SE
- Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis8 Oct 2026US 2026/0306598 A1Cour Pharmaceuticals Development Company, Inc.
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Mucosal vaccines against tuberculosis8 Oct 2026US 2026/0306604 A1University of Houston System
Most cited
By later US patents
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Interleukin-1α antibodies1,029US 8,034,337 B2Xbiotech, Inc. · 2011
- Antigen-adjuvant compositions and methods1,024US 8,790,658 B2Sanofi Pasteur Limited · 2014
- Saponin adjuvant520US 5,057,540 ACambridge Biotech Corporation · 1991
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001